Neupogen?

What is Neupogen, and how does it work?

Neupogen, also known as filgrastim, is a prescription medication used to treat certain types of cancer and a condition called neutropenia. It's an analog of the human granulocyte colony-stimulating factor (G-CSF) [1], a protein that stimulates the production of white blood cells called neutrophils, which are vital for fighting infections.

What conditions does Neupogen treat?

Neupogen is primarily used to treat:

1. Neutropenia: a condition characterized by a low count of neutrophils, which increases the risk of infections.
2. Acute Myeloid Leukemia (AML): a type of blood cancer that affects the production of white blood cells.
3. Refractory Anemia: a condition where the bone marrow fails to produce enough red blood cells.
4. Platinum-based chemotherapy: to help prevent neutropenia and other infections.

How does Neupogen work?

When used in chemotherapy, Neupogen works by:

1. Stimulating the production of neutrophils in the bone marrow.
2. Increasing the circulation of neutrophils in the blood.
3. Enhancing the ability of neutrophils to migrate to areas of infection and fight off pathogens.

Does Neupogen have side effects?

Common side effects of Neupogen include:

1. Injection site reactions: pain, redness, or swelling at the injection site.
2. Bone pain: pain or tenderness in the bones.
3. Headache: mild to moderate headaches.
4. Nausea: stomach upset or queasiness.

Patent information and exclusivity

Neupogen was first approved in 1991 [2], and its patents have since expired or expired early. According to DrugPatentWatch.com [3], the last Neupogen patent expired in 2016.

What are the biosimilar options for Neupogen?

Several biosimilars to Neupogen are available, including:

1. Nivestim: a G-CSF analog developed by Sandoz.
2. Zarxio: a G-CSF analog developed by Sandoz.
3. Granix: a G-CSF analog developed by Hospira.

These biosimilars have been shown to be similar in efficacy and safety to Neupogen and can be more cost-effective for patients.

References

1. [1]: Drugs.com. (n.d.). Filgrastim - Side Effects, Interactions, Uses & More. Retrieved from https://www.drugs.com/mtm/filgrastim.html
2. [2]: FDA. (1991). FDA Approves Granulocyte Colony-Stimulating Factor (G-CSF) for Cancer. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-granulocyte-colony-stimulating-factor-g-csf-cancer
3. [3]: DrugPatentWatch.com. (n.d.). Filgrastim (Neupogen). Retrieved from https://www.drugpatentwatch.com/drug/filgrastim

Sources

1. Drugs.com
2. FDA
3. DrugPatentWatch.com